65,437 trials
Sarcoma
Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants
SARS-CoV-2 Infection
Primary: SARS-CoV-2 Infection as Measured by Patient Report of Clinically Confirmed COVID-19 (or Viral PCR When Available) — 68; 50; 48; 30 Participants — p=0.10
Metastatic Breast Cancer
Primary: Overall Survival (OS) for Commonly Prescribed First-line Treatment Strategies — 23.7; 13.5; 30.9; 17.4 months
Treatment
Primary: 1-year Progression Free Survival Rate — 9; 18 Participants
Rectal Cancer
Primary: Neoadjuvant Response (NAR) Score — 9.31 Calculated score
Obesity
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0; 2; 5; 6 participants
Gastro Intestinal Stromal Tumor
Primary: Time to Next Treatment (TNT) — 26.7 months
Concussion Mild
Primary: Post Traumatic Growth — 41.7; 57.8; 40.4; 60.7 Score on a scale
Fibromyalgia
Primary: Conditioning Pain Modulation (CPM) — 0.36; 0.05; 0.21; -0.55 Unit on a scale (NPS 0-10)
Advanced or Metastatic Solid Tumors
Primary: Phase 1: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) — 3; 6; 33; 19 Participants
Polycystic Kidney, Autosomal Dominant
Primary: Estimated Slope of Total Kidney Volume During Pre-administration and Administration — 6.7517; 3.6811 %/year
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Suicide
Primary: Suicide Events — 1.8; 3.0 number of events
Healthy Volunteers
Primary: Resting-state Electroencephalogram (EEG) — 0.016; -0.025 Difference in alpha asymmetry (µV²).
Cigarette Smoking-Related Carcinoma · Tobacco-Related Carcinoma
Primary: Usual Brand Cigarettes Per Day — 15.803; 2.1563; 1.8353; 1.4931 Cigarettes per Day